Bayer’s experimental stroke drug could reshape secondary stroke prevention
Millions of stroke survivors across the world may soon have a new defense
Millions of stroke survivors across the world may soon have a new defense
Paxton alleges the companies marketed Plavix as a reliable defense against heart attacks, strokes, and blood clots while failing to disclose evidence that the drug could be ineffective or virtually useless for many people
Topline results from the Phase 2 VISTA trial show that PIPE-307 did not meet its primary or secondary efficacy endpoints
The drug is being tested for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction
The study successfully met its primary endpoint, demonstrating similar rates of viral suppression for DOR/ISL compared to Biktarvy at 48 weeks
The formulation is backed by over 80 clinical trials and 200 scientific publications
The facility will offer fully equipped wet labs and strategic scientific support for early-stage biotech companies
Subscribe To Our Newsletter & Stay Updated